Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.74 |
| ▸ | MAPT | P10636 | 1/20 | 0.71 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.69 |
| ▸ | BCHE | P06276 | 1/20 | 0.69 |
| ▸ | ACHE | P22303 | 1/20 | 0.69 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.55 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.55 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12614534 | 0.93 | ALDH1A1 (0.69) | ALDH1A1MAPTCHRNA7BCHEACHE | |
| SCHEMBL4408602 | 0.85 | ALDH1A1 (1.00) | ALDH1A1MAPTCHRNA7BCHEACHE | |
| SCHEMBL372960 | 0.85 | CHRNA7 (0.72) | ALDH1A1MAPTCHRNA7BCHEACHE | |
| SCHEMBL12614601 | 0.85 | ALDH1A1 (0.66) | ALDH1A1MAPTCHRNA7BCHEACHE | |
| SCHEMBL12615036 | 0.84 | CHRM2 (0.74) | ALDH1A1MAPTCHRNA7BCHEACHE | |
| SCHEMBL7364408 | 0.83 | MAPT (0.74) | ALDH1A1MAPTCHRNA7BCHEACHE | |
| SCHEMBL7366410 | 0.83 | MAPT (1.00) | ALDH1A1MAPTCHRNA7BCHEACHE | |
| SCHEMBL13595966 | 0.83 | MAPT (0.74) | ALDH1A1MAPTCHRNA7BCHEACHE | |
| SCHEMBL7365487 | 0.83 | MAPT (0.74) | ALDH1A1MAPTCHRNA7BCHEACHE | |
| SCHEMBL372135 | 0.82 | CHRNA7 (1.00) | ALDH1A1MAPTCHRNA7BCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060160835-A1 | Methods and compositions for treatment of central nervous system disorders | BENCHERIF MEROUANE | 2006-07-20 | — | — | US | claimed |
| US-7067261-B2 | Methods and compositions for treatment of central nervous system disorders | TARGACEPT, INC. (US) | 2006-06-27 | — | — | US | claimed |
| EP-0885221-B1 | AZABICYCLIC ESTERS OF CARBAMIC ACIDS USEFUL IN THERAPY | ASTRAZENECA AB (SE) | 2002-06-12 | — | — | EP | claimed |
| US-5998429-A | Azabicyclic esters of carbamic acids useful in therapy | ASTRA AB (SE) | 1999-12-07 | — | — | US | claimed |
| EP-0885221-A1 | AZABICYCLIC ESTERS OF CARBAMIC ACIDS USEFUL IN THERAPY | Astra Aktiebolag (SE) | 1998-12-23 | — | — | EP | claimed |
| WO-1997030998-A1 | AZABICYCLIC ESTERS OF CARBAMIC ACIDS USEFUL IN THERAPY | ASTRA AKTIEBOLAG (SE) | 1997-08-28 | — | — | WO | claimed |
| US-20140234270-A1 | TREATMENT WTH ALPHAT SELECTIVE LIGANDS | TARGACEPT, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| EP-2484363-A1 | (2S,3R)-N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-5-methylthiophene-2-carboxamide | Targacept, Inc. (US) | 2012-08-08 | — | — | EP | disclosed |
| EP-2409703-A1 | Treatment with alpha7-selective ligands | Targacept, Inc. (US) | 2012-01-25 | — | — | EP | disclosed |
| US-20110262407-A1 | TREATMENT WITH ALPHA7 SELECTIVE LIGANDS | TARGACEPT, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| EP-2364150-A1 | TREATMENT WITH ALPHA 7-SELECTIVE LIGANDS | Targacept Inc. (US) | 2011-09-14 | — | — | EP | disclosed |
| US-20110124678-A1 | TREATMENT WITH ALPHA 7-SELECTIVE LIGANDS | TARGACEPT, INC. (US) | 2011-05-26 | — | — | US | disclosed |
| WO-2010056622-A1 | TREATMENT WITH ALPHA α7-SELECTIVE LIGANDS | TARGACEPT, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| US-20060160835-A1 | Methods and compositions for treatment of central nervous system disorders | BENCHERIF MEROUANE | 2006-07-20 | — | — | US | disclosed |
| US-7067261-B2 | Methods and compositions for treatment of central nervous system disorders | TARGACEPT, INC. (US) | 2006-06-27 | — | — | US | disclosed |
| EP-0885221-B1 | AZABICYCLIC ESTERS OF CARBAMIC ACIDS USEFUL IN THERAPY | ASTRAZENECA AB (SE) | 2002-06-12 | — | — | EP | disclosed |
| US-6054464-A | Azabicyclic esters of carbamic acids useful in therapy | ASTRA AKTIEBOLAG (SE) | 2000-04-25 | — | — | US | disclosed |
| US-5998429-A | Azabicyclic esters of carbamic acids useful in therapy | ASTRA AB (SE) | 1999-12-07 | — | — | US | disclosed |
| EP-0885221-A1 | AZABICYCLIC ESTERS OF CARBAMIC ACIDS USEFUL IN THERAPY | Astra Aktiebolag (SE) | 1998-12-23 | — | — | EP | disclosed |
| WO-1997030998-A1 | AZABICYCLIC ESTERS OF CARBAMIC ACIDS USEFUL IN THERAPY | ASTRA AKTIEBOLAG (SE) | 1997-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160835-A1 | Methods and compositions for treatment of central nervous system disorders | JAK2, ERBB2, ERBB3 | ALDH1A1 3577/4885MAPT 961/4885CHRNA7 46/4885 |
| US-20140234270-A1 | TREATMENT WTH ALPHAT SELECTIVE LIGANDS | CHRNA7, CHRNA2, CHRNA4 | ALDH1A1 1381/4885MAPT 212/4885CHRNA7 1/4885 |
| US-20110124678-A1 | TREATMENT WITH ALPHA 7-SELECTIVE LIGANDS | CHRNA7, CHRNA1, CHRNG | ALDH1A1 993/4885MAPT 3008/4885CHRNA7 1/4885 |
| US-20110262407-A1 | TREATMENT WITH ALPHA7 SELECTIVE LIGANDS | CHRNA7, CHRNA4, CHRNA2 | ALDH1A1 1040/4885MAPT 1251/4885CHRNA7 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.